BiomX Inc. (PHGE)

0.3500 +0.0140 (+4.17%) At close: 03:59PM EDT

BiomX Inc.

22 Einstein Street
Floor 4
Ness Ziona 7414003
Israel
972 7 2394 2377
https://www.biomx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 58

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jonathan Eitan Solomon MBA	CEO & Director	714.37k	N/A	1977
Dr. Merav Bassan Ph.D.	Chief Development Officer	437.71k	N/A	1966
Ms. Marina Wolfson CPA	CFO & Secretary (Leave of Absence)	337.51k	N/A	1984
Prof. Rotem Sorek Ph.D.	Scientific Founder	N/A	N/A	N/A
Dr. Eran Elinav M.D., Ph.D.	Scientific Founder	N/A	N/A	N/A
Dr. Timothy K. Lu M.D., Ph.D.	Scientific Founder	N/A	N/A	1981
Mr. Avraham Gabay	Interim Chief Financial Officer	N/A	N/A	1986
Ms. Inbal Benjamini-Elran	C.H.R.O	N/A	N/A	N/A
Mr. Assaf Oron	Chief Business Officer	352.04k	N/A	1974

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Corporate governance

BiomX Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.